타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt) Regeneron·BCMA × CD3 24 trials·t½ IgG-like, supporting weekly then less frequent dosing |
|---|---|
Overview Program | Lynozyfic (linvoseltamab) |
Overview Company | Regeneron |
Overview Modality | ANTIBODY |
Overview Target | BCMA × CD3 |
Overview Indication | Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen. |
Positioning Known limitation | BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy. |
Positioning Development positioning | 4L+ |
MoA Mechanism | Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity. |
MoA Biomarker | BCMA expression is not a companion diagnostic; soluble BCMA is exploratory. |
PK/PD Half-life | IgG-like, supporting weekly then less frequent dosing |
PK/PD Species | ORR, MRD, soluble BCMA |
PK/PD Animal (cat.) | Human |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. |
Toxicology CRS | CRS common, mostly grade 1–2 with step-up |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. |
Clinical Program phase | APPROVED |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt) Regeneron·BCMA × CD3 24 trials·t½ IgG-like, supporting weekly then less frequent dosing |
|---|---|
Overview Program | Lynozyfic (linvoseltamab) |
Overview Company | Regeneron |
Overview Modality | ANTIBODY |
Overview Target | BCMA × CD3 |
Overview Indication | Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen. |
Positioning Known limitation | BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy. |
Positioning Development positioning | 4L+ |
MoA Mechanism | Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity. |
MoA Biomarker | BCMA expression is not a companion diagnostic; soluble BCMA is exploratory. |
PK/PD Half-life | IgG-like, supporting weekly then less frequent dosing |
PK/PD Species | ORR, MRD, soluble BCMA |
PK/PD Animal (cat.) | Human |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. |
Toxicology CRS | CRS common, mostly grade 1–2 with step-up |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. |
Clinical Program phase | APPROVED |
추천 비교
추천 비교